YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
MannKind (MNKD) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to break-even earnings per share a year ago. These figures are adjusted for non-recurring items. This q…
CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designe…
(RTTNews) - Today's top biotech gainers include Universe Pharmaceuticals, which recently filed its SEC report for the six months ended March 31, 2026; Cumberland Pharma, ahead of its second-quarter 2026 financial results due Tuesday; and A…
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.1. This compares to a loss of $1.29 per share a year ago. These figures are adjusted for non-recurring item…
CAMBRIDGE, Mass., July 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designe…
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Aytu BioPharma, Inc. AYTU is a pharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 5.8% downward over the last 60 da…
We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. CAMP4 THERAPEUTICS CORPORATION (NASDAQ:CAMP) is one of the best up and coming stocks on our list. TheFly reported on June 16 that JPMorgan upgraded C…
BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the appointment of Kelly Gold to the Company’s Board of Director…
CAMBRIDGE, Mass., June 19, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designe…
VANCOUVER, British Columbia, June 08, 2026 (GLOBE NEWSWIRE) -- Canadian GoldCamps Corp. (CSE: CAMP) (OTC: SMATF) (FSE: A68) announces the receipt of new gold analytical results from a high-resolution re-sampling program completed on drill…
Key Points HarbourVest initiated 1,722,210 shares of Generate Biomedicines last quarter; the estimated trade size was $21.03 million based on quarterly average prices. The quarter-end position value increased by $21.53 million, reflecting…
On May 15, 2026, HarbourVest Partners disclosed a new position in Generate Biomedicines(NASDAQ:GENB), acquiring 1,722,210 shares in the first quarter. The estimated transaction value is $21.03 million, based on quarterly average pricing. W…
(RTTNews) - CAMP4 Therapeutics Corporation (CAMP), a clinical-stage biopharmaceutical company, on Thursday released its first-quarter financial results and provided various business highlights. The company specializes in developing RNA-tar…
5AM Venture Management disclosed a full exit from Dianthus Therapeutics(NASDAQ:DNTH) on February 17, 2026, selling 365,053 shares worth $14.36 million in the fourth quarter. What happened According to a Securities and Exchange Commission (…
Key Points 5AM Venture Management sold 365,053 shares of Dianthus Therapeutics in the fourth quarter. The quarter-end position value decreased by $14.36 million as a result of the sale, which marked a full exit from Dianthus. The position…
On February 17, 2026, 5AM Venture Management reported selling its entire stake in Praxis Precision Medicines(NASDAQ:PRAX), an estimated $9.01 million trade based on last-disclosed position values. What happened According to a Securities an…
CAMBRIDGE, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designe…
VANCOUVER, British Columbia, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Canadian GoldCamps Corp. (CSE: CAMP)(OTC: SMATF) (FSE: A68) (the “Company”) is pleased to announce management and board changes, a non-brokered private placement financing to r…
Key Points San Francisco-based 5AM Venture Management sold 150,000 CNTA shares in the third quarter. Despite the sale, the stock's sharp rally last quarter led the fund's net position value in CNTA to increase by $5.6 million. 5AM still ho…
Key Points San Francisco-based 5AM Venture Management sold 150,000 CNTA shares in the third quarter. Despite the sale, the stock's sharp rally last quarter led the fund's net position value in CNTA to increase by $5.6 million. 5AM still ho…
Key Points Exited entire position: down 189,593 shares, a net position change of $5.02 million No remaining shares held; post-trade stake is zero The position previously accounted for approximately 1.9% of the fund’s AUM in the prior quart…
Key Points Sold 282,313 shares for an estimated $13.33 million net change Post-sale, the fund holds zero shares valued at $0 The position was previously 5.12% of the fund’s assets as of last quarter These 10 stocks could mint the next wave…
CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designe…
* Camp4 Therapeutics press release [https://seekingalpha.com/pr/20297823-camp4-reports-third-quarter-2025-financial-results-and-corporate-highlights] (CAMP [https://seekingalpha.com/symbol/CAMP]): Q3 Net loss for the quarter ended Septembe…
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designe…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Elevate Your Investing Strategy: Take advantage of TipRank…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Arete upgraded Baidu (BIDU) to Buy from Se…
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE COMMENT STSS…
Camp4 Therapeutics (CAMP) said Wednesday that it has signed agreements with certain investors to rai PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Oversubscribed Financing led by Coastlands Capital with participation from new and existing investors Financing to provide $50 million in upfront proceeds with the potential for up to an additional $50 million of proceeds to fund the Phase…
Crypto Daybook Americas will not be published on Monday due to the Labor Day holiday. It will return on Tuesday. By Omkar Godbole (All times ET unless indicated otherwise) Bitcoin (BTC) has dropped nearly 3% to $109,800 in the past 24 hour…
New board members bring decades of experience in company building, corporate strategy, drug development, and commercialization across multiple therapeutic areas CAMBRIDGE, Mass., August 19, 2025--(BUSINESS WIRE)--eGenesis, a biotechnology…
* Camp4 Therapeutics press release [https://seekingalpha.com/pr/20201852-camp4-reports-second-quarter-2025-financial-results-and-corporate-highlights] (NASDAQ:CAMP [https://seekingalpha.com/symbol/CAMP]): Q2 GAAP EPS of -$0.62 beats by $0.…
Key Points Revenue (GAAP) reached $1.497 million, surpassing analyst estimates and marking the company's first material recognized revenue. GAAP net loss per share narrowed to $(0.62). Cash and cash equivalents were $39.1 million, with con…
Haploinsufficient SYNGAP1 mice treated with CMP-SYNGAP-01 demonstrated an increase in SYNGAP1 protein levels; treatment rescued multiple SYNGAP1-dependent behavioral phenotypes CMP-SYNGAP-01 administration led to a significant increase in…
Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in multiple ascending dose (MAD) cohort 3; safety, pharmacokinetic, and pharmacodynamic data expected Q4 2025CTA successfully submitted in…